Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$112.48B |
$55.27
-2.38%
|
|
CVS
CVS Health Corporation
CVS retails OTC analgesics and related pain relief products.
|
$99.69B |
$78.59
-3.40%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$77.69B |
$732.71
-1.24%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$59.36B |
$207.11
-0.60%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX launched the IDEXX Cancer Dx panel, a cancer diagnostic test aligned with companion diagnostics for oncology.
|
$57.23B |
$715.06
+0.41%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$55.24B |
$124.63
-0.52%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$50.73B |
$212.35
-0.52%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$50.48B |
$16.16
-1.04%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$48.61B |
$800.02
-1.63%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$47.09B |
$358.97
-0.08%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$44.89B |
$9.84
+0.67%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$40.41B |
$237.75
-1.46%
|
|
A
Agilent Technologies, Inc.
BIOVECTRA acquisition expands Agilent's contract manufacturing capabilities (CDMO) for advanced modalities.
|
$39.59B |
$139.62
-3.60%
|
|
ALC
Alcon Inc.
Alcon markets ophthalmic drugs and prescription eye drops like Tryptyr.
|
$39.06B |
$78.99
-0.85%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare markets proprietary radiopharmaceuticals (e.g., Flyrcado) and radiopharmaceutical diagnostics.
|
$37.32B |
$81.72
-0.95%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$37.25B |
$337.87
-0.12%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$34.12B |
$161.53
+1.42%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$33.01B |
$17.20
-0.35%
|
|
JBL
Jabil Inc.
Aseptic filling and dry oral dosage capabilities via Pharmaceutics International (Pii) reflect contract manufacturing services in pharma.
|
$26.85B |
$251.39
-0.71%
|
|
BNTX
BioNTech SE
BioNTech develops and sells vaccines, including its mRNA vaccine platform, a core direct product category.
|
$26.20B |
$109.00
+2.76%
|
|
BIIB
Biogen Inc.
Biogen's LEQEMBI is an Alzheimer's disease therapeutic, a direct product the company manufactures and sells.
|
$24.11B |
$164.38
-2.48%
|
|
LH
Labcorp Holdings Inc.
Labcorp functions as aContract Research Organization offering outsourced drug development and regulatory support services.
|
$22.51B |
$270.99
+0.78%
|
|
RVMD
Revolution Medicines, Inc.
Clinical-stage biotech focused on oncology; primary products are RAS(ON) inhibitors for cancer.
|
$22.48B |
$120.36
-2.36%
|
|
UTHR
United Therapeutics Corporation
UTHR's core PAH/CV therapy portfolio centers on prostacyclin cardiovascular drugs, including Tyvaso, Remodulin, Orenitram, and Ralinepag (where applicable).
|
$21.03B |
$464.94
-1.49%
|
|
INCY
Incyte Corporation
Incyte's business is centered on oncology-focused therapeutics, including Monjuvi and a broad cancer pipeline.
|
$20.74B |
$106.17
+0.88%
|
|
GMAB
Genmab A/S
Genmab is a biotechnology company focused on oncology therapeutics, fitting Biotech - Oncology.
|
$20.69B |
$32.26
-4.70%
|
Showing page 2 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
